Pill aims to rebuild Worn-Out knee cartilage

NCT ID NCT05816395

Summary

This study tested whether a new oral medication called RHH646 could help regrow cartilage in the knees of people with mild to moderate osteoarthritis. Over 80 participants took the drug or a placebo for one year while researchers used MRI scans to measure changes in knee cartilage volume and monitored safety. The goal was to see if the drug could slow or reverse cartilage damage, potentially offering a new way to manage the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS, KNEE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinical Trial Network

    Houston, Texas, 77074, United States

  • Clinical Trials Research

    Lincoln, California, 95648, United States

  • Conquest Research

    Winter Park, Florida, 32789, United States

  • Novartis Investigative Site

    Buenos Aires, C1055AAF, Argentina

  • Novartis Investigative Site

    Caba, C1015ABO, Argentina

  • Novartis Investigative Site

    Gandrup, 9362, Denmark

  • Novartis Investigative Site

    Herlev, 2730, Denmark

  • Novartis Investigative Site

    Warsaw, 00-874, Poland

  • Novartis Investigative Site

    Santiago, A Coruna, 15705, Spain

  • Pioneer Research Solutions

    Sugar Land, Texas, 77479, United States

Conditions

Explore the condition pages connected to this study.